N17350 for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Jan 2026: Trial registered, NCT07339176
  2. 25 May 2026: Trial started, NCT07339176

The trials

NCT07339176: Intratumoral N17350 in Advanced Solid Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
275 planned
Started
25 May 2026
Primary completion
Jul 2028
Arms
N17350 Intratumoral Injection 1 mg/ml superficial lesions, N17350 Intratumoral Injection 2 mg/ml superficial lesions, N17350 Intratumoral Injection 4 mg/ml superficial lesions, N17350 Intratumoral Injection 2 mg/ml visceral lesions, N17350 Intratumoral Injection 4 mg/ml visceral lesions, N17350 Intratumoral Injection for cuSCC, N17350 Intratumoral Injection for Melanoma, N17350 Intratumoral Injection for SCCHN, N17350 Intratumoral Injection for NSCLC, N17350 Intratumoral Injection for TNBC
Results
None posted
  1. 14 Jan 2026: Trial registered
  2. 25 May 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.